Meeting the Challenges in Cancer Care Management During the SARS-CoV-2 Pandemic: A Retrospective Analysis

Marika Rasschaert¹, Pieterjan Vanclooster¹, Laura Depauw¹, Tim Mertens¹, Ella Roelant², Elke Coenen³, Sebastien Anguille⁴, Annelies Janssens⁵, Peter Van Dam⁶,⁷,*, and Marc Peeters¹,⁷,*

Abstract

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has overwhelmed the capacity of healthcare systems worldwide. Cancer patients, in particular, are vulnerable and oncology departments drastically needed to modify their care systems and established new priorities. We evaluated the impact of SARS-CoV-2 on the activity of a single cancer center.

Methods: We performed a retrospective analysis of (i) volumes of oncological activities (2020 vs 2019), (ii) patients’ perception rate of the preventive measures, (iii) patients’ SARS-CoV-2 infections, clinical signs thereof, and (iv) new diagnoses made during the SARS-CoV-2 pandemic.

Results: As compared with a similar time frame in 2019, the overall activity in total numbers of outpatient chemotherapy administrations and specialist visits was not statistically different (P = .961 and P = .252), while inpatient admissions decreased for both medical oncology and thoracic oncology (18% (P = .0018) and 44% (P < .0001), respectively). Cancer diagnosis plummeted (~34%), but no stage shift could be demonstrated. Acceptance and adoption of hygienic measures was high, as measured by a targeted questionnaire (>85%). However, only 46.2% of responding patients regarded telemedicine, although widely deployed, as an efficient surrogate to a consultation.

Thirty-three patients developed SARS-CoV-2, 27 were hospitalized, and 11 died within this time frame. These infected patients were younger, current smokers, and suffered more comorbidities.

Conclusions: This retrospective cohort analysis adds to the evidence that continuation of active cancer therapy and specialist visits is feasible and safe with the implementation of telemedicine. These data further confirm the impact of SARS-CoV-2 on cancer care management, cancer diagnosis, and impact of infection on cancer patients.

Keywords

SARS-CoV-2, COVID-19, cancer care, telehealth, e-health
Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a ribonucleic acid coronavirus, similar to SARS-CoV-1 and Middle East respiratory syndrome coronavirus.\(^3\) The genome of the virus demonstrates 96% of concordance with the genome of a bat coronavirus suggesting its potential origin.\(^3,4\)

SARS-CoV-2 was first identified in humans in December 2019 and presented as a severe viral pneumonia.\(^5\) As SARS-CoV-2 spread rapidly, this virus challenged the world’s finite health resources and the traditional healthcare delivery system, forcing immediate change in health management that is likely to last for a prolonged time.

Traditionally, cancer patients especially were regarded as at higher risk for SARS-CoV-2 transmission and disease because of the underlying disease, but also due to comorbid conditions and treatment-related immune dysfunction. Early data from China seemed to confirm the higher infection rates,\(^6\) but these were later contradicted\(^7,8\) and ultimately refined as the United Kingdom—researchers demonstrated a differential susceptibility relative to tumor type.\(^3\) Similar to patients without cancer, the severity or fatality rate in cancer patients is confounded by factors such as age, gender, cardiovascular morbidities, obesity, diabetes, and even tumor type.\(^10\)–\(^13\) Still, when cancer patients suffer severe SARS-CoV-2, the in-hospital mortality rate is higher compared to non-oncology patients, particularly in patients with metastatic disease and patients with hematological cancers.\(^14,15\)

The SARS-CoV-2 forced oncology professionals to navigate—mostly centralized—cancer care with shortages of resources and the possibility of a potential higher transmission exposure. The scientific community responded with adjusted guidelines in order to provide the safe and efficient care to all; all of which are based on broad consensus and expert peer review.\(^16\)–\(^20\)

In order to present a real-world experience, we report in this single-center cohort analysis the changes implemented during the first peak of the SARS-CoV-2 pandemic and the evolution in oncologic care activities and diagnoses. In addition, we evaluated the patients’ perception of the safety measures and finally describe the SARS-CoV-2 prevalence and comorbidity in a cohort of cancer patients treated at a tertiary care hospital in Belgium.

Material and Methods

Study Design, Data Sources, and Collection

We report a retrospective analysis of the clinical activity at the Antwerp University Hospital Cancer Center (MOCA) from March 17th to August 28th (week 8 until 34), and compared these data to the data of the same period in 2019.

We evaluated the effect of SARS-CoV-2 preventive measures on volumes of oncological activity by tracking the (1) number of consultations, the (2) number of outpatient treatments, (3) hospital admissions (pre-planned and not), and finally (4) the number of new cancer diagnoses presented to the multidisciplinary oncology boards. (Supplementary methods).

All cancer patients with a laboratory confirmed SARS-CoV-2 infection; both out- and inpatients at the Antwerp University Hospital were identified by reviewing medical charts and by screening for patients with positive nasopharyngeal polymerase chain reaction test from March 17th to August 28th. The clinical data such as patient demographics, comorbidities (including history of cancer), and clinical presentation were retrieved from electronic medical records after anonymization.

The clinical data were compared to a population-based national dataset obtained by the Belgian public health institute (Sciensano) and published in literature. This dataset concerns 13594 confirmed SARS-CoV-2 hospitalized patients (1187 with a solid cancer), and were retrieved by Sciensano, on May 24, 2020.\(^15\)

Patient-Reported Perception of Organizational Measures

To assess patients’ perception of risks, their fears, and the acceptance of protective/organizational measures, anonymous questionnaires (Supplementary methods), approved by the Antwerp University Hospital psycho-oncology service, were administered at triage to all patients accessing our outpatient facilities over a 28-day period; questionnaires were returned on a voluntary basis.

Statistical Analysis

Qualitative variables were presented with the observed numbers and percentages. For oncological activity volumes, 27 weekly average and total numbers +/- standard deviations were reported for weeks 8 until 35 of 2019 and 2020. Variations and differences in average activity volumes between the two periods were compared. Normality per group was tested with a Kolmogorov-Smirnov test and if normality was acceptable per group an independent samples t-test was used, if not a Mann–Whitney test. The Levene’s test evaluated if equal variances could be assumed, if not a Welch t-test was used.

The answers to relevant questionnaire items are reported as percentages. When evaluating cancer diagnosis made during a similar period in 2019 as in 2020, numbers were described for 4 solid tumor types and per type the distribution of the stages between 2019 and 2020 was compared using a chi-square test or Fisher’s exact test as appropriate.

The clinical characteristics of SARS-CoV-2-infected patients were compared to a national dataset (15) using a chi-square test for the categorical variables and a Fisher’s exact test if more than 20% of the expected values were lower than
5. The corresponding odds ratio with 95% confidence interval was also calculated. For the age as continuous variable, the Welch t-test was used. The statistical analysis was done using SPSS version 21, and non-parametric confidence interval for odds ratio was computed in R-3.5.2 for Windows.

Results

SARS-CoV-2-Related Events and Organizational Protective Measures

The first Belgian SARS-CoV-2-infected patient was diagnosed on February 3rd, 2020, after his return flight from China. On February 29th, the first patient was hospitalized and treated at the Antwerp University Hospital; from that point onward, health measures were issued, such as issuing necessary protective shielding or FFP2 masks, regulating access to the institution and work-related travel. Governmental restrictions (“lockdown rules”) to prevent the spread of SARS-CoV-2 in Belgium were issued on March 13th, 2020. The Antwerp University Hospital Cancer Center expanded on these measures to further ensure safe cancer care. Follow-up visits were delayed and rationalized according to expert-based guidelines. Telehealth, both tele-consultations and tele-monitoring, was implemented and expanded upon. Tele-monitoring used an adapted form of a standardized toxicity reporting system to also evaluate COVID-19-related symptoms. This clinician supervised e-tool was proposed to all outpatients receiving active treatment (additional data). In addition, a remote blood draw one day prior to the outpatient treatment shortened their stay at the oncology ward. Finally, a routine SARS-CoV-2 saliva testing was performed every fourth night (as soon as available) (Table 1).

Overall Volumes of Oncology Activities

Between February 17th and August 28th, 2020, we evaluated the volumes of clinical oncological activity and compared them to the activities from a similar period in 2019. During these first months of the SARS-CoV-2 pandemic, local and regional public health authorities prioritized urgent help. Since cancer care was defined as urgent care, all ongoing systemic therapies were continued and new treatments were initiated following careful evaluation of necessity (Supplementary data file).

The number (2020: mean = 12.8, 2019: mean = 15.6) of inpatient admissions of oncology patients diminished with 18% (P = .018 using weekly averages), while outpatient therapies (2020: mean = 117.1, 2019: mean = 117) remained unchanged. The shift from in-hospital treatment to outpatient therapy was even more pronounced for thoracic oncology patients, as demonstrated by a significant increase in outpatient therapy (2020: mean = 18.4, 2019: mean = 16.2) (+14%, P = .04). Considering gynecological oncological surgery, we did not demonstrate differences in in- or outpatient admissions or consultations between 2019 and 2020 (Table 2).

Table 1. Cancer-specific protective measures provided by the Belgian authorities, the European Society of Medical Oncology (ESMO) and adapted by the Antwerp University Hospital.

| Category                  | Belgian MoH / Sciensano                                      | ESMO (21)                                      | Antwerp University Hospital                                                                 |
|---------------------------|--------------------------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------|
| Triage                    | No reference to triage                                       | No access until evaluation by healthcare professional of COVID-19 related symptoms. | Physical triage at entrance of hospital “Previous day” telephone triage or e-questionnaire concerning COVID-19 related symptoms. Attribution of color-coded entrance. |
| Active Cancer Care        | Local Health authorities and each hospital should identify urgent from non-urgent care and guarantee safe administration of essential treatments | Prioritize adjuvant therapies Discuss benefits and risks of present cancer therapy, treatment setting, disease prognosis, patients comorbidities and patients preferences. Reduce number of visits or re-evaluate treatment schedules. | No interruption or delay of active cancer care (both curative and palliative intent) Color coded entrance and patient flow E-registry of toxicity and COVID-19 related symptoms. “previous day” remote blood test organized in concert with care center. Saliva test / every 14 days. Pre-validation of Cancer treatment Shortening of “chair time” Non-urgent FU visits suspended. Telephone and e-mail contacts to allow evaluation of lab and imaging. Visits following diagnostic evaluation or exams remain possible |
| Follow up                 | Post pone where possible and in accordance with specialists. Re-imbursement of telephone consultation | Tele health and Digital health: tools for consultations and counseling should be improved to support patients remotely and meet their needs. | Non-urgent FU visits suspended. Telephone and e-mail contacts to allow evaluation of lab and imaging. Visits following diagnostic evaluation or exams remain possible |
| Caregiver                 | No reference to caregivers                                   | No reference to caregivers                    | Not for active treatment. One caregiver allowed in case of necessity, end of life (inpatient) and treatment-related decisions. |
In-hospital consultations with oncology specialists did not demonstrate statistical meaningful differences between 2019 and 2020 (oncology: mean = 148.7 vs mean = 142, respectively; \( P = .252 \)).

**Diagnoses**

We retrospectively evaluated all new cancer diagnoses made at the Antwerp University Hospital Cancer Center during the period from February to July 2019 and 2020, for which a registration to the National Cancer Registry was made. The overall incidence of solid tumor plummeted with 34%. (818 and 1243 incidences in 2019 and 2020, respectively). In order to evaluate stage migration because of delayed presentation, we evaluated 4 major solid tumor types: breast, colorectal, lung, and prostate cancer. All of which were profoundly less frequently diagnosed in 2020 (136, 43, 106, and 48) compared to 2019 (210, 59, 120, and 86). There was no statistical difference when evaluating the 2019 and 2020 cohort per tumor type and stage (e.g., breast (\( P = .995 \)), CRC (\( P = .152 \)), lung (\( P = .474 \)), and prostate (\( P = .535 \))).

**Questionnaire on the Knowledge About and Acceptance of Risk-Mitigating Protective Measures**

We sent out a questionnaire in a cohort of outpatients (n = 119); the questions regarded organization and implementation of the coronavirus disease 2019 (COVID-19) protective measures at the hospital and oncology clinic; the acceptance thereof by cancer patients; and anxiety concerning infection risk, regardless of these measures. The demographics of the 119 responders can be reviewed in supplementary data file.

A majority of patients were knowledgeable about the protective measures (88%), most declared to have received this information at the entrance of the hospital (billboards) or subsequently at the triage gate following the entrance of the hospital (69 and 7.6%).

Apprehension for waiting rooms or other hospital facilities was little and patients felt safe 73.1% and 79.8%, respectively. Contrary and perhaps as a consequence, patients were somewhat reluctant to regard e-health/ phone-based consultations as a valid surrogate (46.2% thought this to be an alternative and 34.5% only quite so).

We registered a broad appreciation of the risk-mitigating strategies (68.9% of respondents high and 25.2% quite high); however, slight differences according to specific measures were noted. Wearing a face mask was well accepted by 79.0% (n = 94/119) of patients and isolation within a “domestic cluster” (= a cluster of all people residing under the same roof) or self-quarantine (in case of high-risk contacts) demonstrated feasible for 63.9% (n = 76/119) and 60.5% (n = 72/119); maintaining or restricting to a small social cluster proved less manageable and was appreciated by merely 49.6% (n = 59/119).

46.2% (n = 55/119) of cancer patients claimed to be knowledgeable about the relative interaction of comorbidities

**Table 2.** Changes in volumes of oncology activities during week 8 until 34 2020 as compared with the same period in 2019. Average weekly numbers (calculated over the entire period) ± standard deviation (SD) of inpatient admissions, outpatient admissions and consultations. Overall volumes refer to all disciplines at the Anwerp University Hospital. Oncology refers to Cancer care for solid tumors other than Thoracic Oncology. Gynecological oncology refers to surgical interventions / treatment for gynecologic malignancies.

|                      | 2019 Mean | 2019 SD | 2020 Mean | 2020 SD | P-value |
|----------------------|-----------|---------|-----------|---------|---------|
| Overall              |           |         |           |         |         |
| Inpatient admissions | 570.1     | 50.4    | 443.1     | 121.2   | <.0001† |
| Outpatient admissions| 979.5     | 92.5    | 832.1     | 207.5   | .009*   |
| Consultations        | 10162.3   | 1171    | 7652.8    | 2719    | .0002*  |
| Oncology             |           |         |           |         |         |
| Inpatient admissions | 15.6      | 4       | 12.8      | 3.5     | .018*   |
| Outpatient admissions| 117       | 12.6    | 117.1     | 9       | .961§   |
| Consultations        | 148.7     | 16      | 142       | 25.8    | .252†   |
| Gynecological oncology|           |         |           |         |         |
| Inpatient admissions | 7         | 3.1     | 6.9       | 3.4     | .867§   |
| Outpatient admissions| 5.6       | 2.6     | 4.1       | 3.4     | .083§   |
| Consultations        | 97.9      | 22.2    | 90.4      | 27.4    | .275§   |
| Thoracic oncology    |           |         |           |         |         |
| Inpatient admissions | 4.8       | 1.5     | 2.7       | 1.6     | <.0001* |
| Outpatient admissions| 16.2      | 4       | 18.4      | 3.7     | .040§   |
| Consultations        | 41        | 5.2     | 41        | 8.2     | .621*   |

SD : Standard Deviation.

†Welch T-test.

*MannWhitney test.

§Independent samples T-test.
and SARS-CoV-2, and 38.7% (n = 46/119) of patients answered that they were afraid (or quite afraid) to receiving chemotherapy because of a higher risk of transmission with the SARS-CoV-2 virus (Figure 1).

**SARS-CoV-2 and Clinical Presentation in Cancer Patients**

On August 11th, we retrospectively identified 37 in-and outpatient Cancer patients with a laboratory-confirmed diagnosis of SARS-CoV-2 infection, at the Antwerp University Hospital. Clinical data of 33 of these patients were evaluated; we excluded 4 because no previous contact was retrieved and no clinical data were evaluable in the electronic patient file.

Twenty-seven patients out of thirty-three were hospitalized after SARS-CoV-2 infection of which 1 was treated in the intensive care unit. Eleven patients died. Our dataset described cancer patients who were younger and predominantly male compared to the national dataset of non-cancer patients. We demonstrated more comorbidities (number/per patient: 45.5% had ≥ 3 comorbidities (P = .029)), especially obesity (31.3%, P < .001), hematological cancer (18.2%, P < .0001) and immunosuppressive disorders (57.6%, P < .0001) were more frequent in our patient cohort. Confounding comorbidities such hypertension and cardiovascular diseases were as frequent in our dataset as in the non-cancer patients. Cancer patients more often were current smokers (30.3%, P < .0001) and presented less likely with symptoms before hospitalization (57.6% vs 94.1%, P < .0001). However, if symptoms occurred, they remained similar to the non-cancer patients (Table 3).

We made no analysis on SARS-CoV-2-related outcome due to the small number of SARS-CoV-2-positive cancer patients.

The retrospective cohort of 33 patients were compared to the clinical data from a population-based national dataset obtained by the Belgian public health institute (Sciensano) and published in literature.\(^{15}\)

\(P\) values were used for the univariate comparison between the two groups (patients with solid cancer vs without cancer). We used a chi-square test for the categorical variables and a Fisher’s exact test if more than 20% of the expected values were lower than 5.

OR: odds ratio: The corresponding odds ratio with 95% confidence interval was also calculated. For age, as continuous variable, the Welch t-test was used.

**Discussion**

We report on the continued care provided in a single tertiary cancer center, during the first surge of the SARS-CoV-2 pandemic. As the SARS-CoV-2 pandemic spread globally,
Table 3. Patients baseline characteristics and clinical presentation when infected with SARS-CoV-2. SARS-CoV-2 infected patients with solid cancer (diagnosed at the Antwerp University hospital) are compared with patients without cancer (as presented by Sciensano (15)). P value for the univariate comparison between the two groups (patients with solid cancer vs without cancer). OR for age (as a categorical variable) was adjusted for gender; OR for gender was adjusted for age (as a continuous variable); all other ORs were adjusted for age (as a continuous variable) and gender. Systemic symptoms cluster: presence of fever/chills reported by the patient and/or fatigue; respiratory symptoms cluster: presence of cough, sore throat, rhinorrhea, anosmia and/or shortness of breath; gastrointestinal symptoms cluster: presence of diarrhoea and/or nausea/vomiting; neurological symptoms cluster: presence of headache and/or irritability/mental confusion. Respiratory signs cluster: presence of pharyngeal exudate, dyspnoea/tachypnoea, abnormal pulmonary auscultation and/or abnormal lung imaging; neurological signs cluster: presence of coma and/or convulsions.

| Patients without cancer | Patients with solid cancer | P value | OR (95% CI) |
|-------------------------|---------------------------|---------|-------------|
| Age in years (n = 12407) | Age in years (n = 33)      |         |             |
| Mean (SD) 67.7 (17.1)   | 61.6 (12.9)                | .011†   |             |
| Median (IQR) 70 (55 to 82) | 62 (28 to 82)               |         |             |
| Age in years–n (%)      |                           |         |             |
| <50 1952 (15.7)         | 4 (12.1)                   | .0005‡  | I           |
| 50–59 2002 (16.4)       | 5 (15.2)                   | 1.22 [26.6.15]‡ |             |
| 60–69 2139 (17.2)       | 15 (45.5)                  | 3.42 [1.09.14.18]‡ |             |
| 70–79 2463 (19.9)       | 7 (21.1)                   | 1.39 [35.6.47]‡ |             |
| 80–89 2976 (19.9)       | 2 (6.1)                    | .33 [03.2.29]‡ |             |
| ≥90 875 (7.1)           | 0                          | 0 [0.3.39]‡ |             |
| Gender–n (%)            |                           |         |             |
| Female 5777 (46.9)      | 11 (33.3%)                 | .118‡   | I           |
| Male 6529 (53.1)        | 22 (66.7%)                 | 1.77 [86.3.65]‡ |             |
| Missing 101             | 0                          |         |             |
| Comorbidities–n (%)     |                           |         |             |
| Cardiovascular disease 4128 (33.7) | 16 (48.5) | .064§ | .53 [27.1.05]§ |
| Hypertension 4931 (39.7) | 16 (48.5) | .306§ | .70 [35.1.39]§ |
| Diabetes 2705 (21.8)    | 4 (12.1)                   | .178§   | 2.02 [71.5.75]§ |
| Chronic kidney disease 1548 (12.5) | 3 (9.1)    | .792§ | 1.43 [44.7.31]§ |
| Chronic lung disease 1777 (14.3) | 4 (12.1) | I* | 1.21 [42.4.75]§ |
| Chronic neurological disease 1099 (8.9) | 2 (6.1) | .765* | 1.51 [38.1.01]§ |
| Cognitive disorder 1441 (11.7) | 2 (6.1) | .423* | 2.05 [52.1.76]§ |
| Immunosuppression (incl HIV) 254 (2.1) | 19 (57.6) | <.0001* | .02 [01.0.03]* |
| Hematological cancer 0 | 6 (18.2) | <.0001* | 0 [00.0.002]* |
| Pregnancy 102 (.8) | 0 | I* | Inf [07.0Inf] |
| Postpartum (<6 weeks) 15 (.1) | 0 | I* | Inf [01.0Inf] |
| Obesity 822 (10.4) | 10 (31.3) | .001* | .26 [12.0.61]* |
| Missing 4533 | 1 | |     |
| No comorbidities 3019 (24.3) | 3 (9.1) | .041§ | 3.22 [98.10.54]§ |
| Number of comorbidities–n (%) | | | |
| 0 3019 (24.3) | 3 (9.1) | 1 | |
| 1 3518 (28.4) | 9 (27.3) | 2.57 [64.1.48]* | |
| 2 2787 (22.5) | 6 (18.2) | 2.17 [46.1.34]* | |
| ≥3 3083 (24.9) | 15 (45.5) | 4.90 [138.26.41]* | |
| Current smoker–n (%) | | | |
| No 5936 (47.8) | 20 (60.6) | <.001* | 1 |
| Yes 660 (5.3) | 10 (30.3) | 4.50 [187.10.11]* | |
| Unknown 5811 (46.8) | 3 (9.1) | .15 [03.0.52]* | |
| Influenza vaccine–n (%) | | | |
| No 913 (7.4) | 0 | I* |     |
| Yes 825 (6.7) | 1 (3) | Inf [03.0Inf] | |
| Unknown 10669 (86.0) | 32 (97) | Inf [70.0Inf] | |
| Timing of symptoms onset -n (%) | | | |
| Before or day of hospitalization 11680 (94.1) | 19 (57.6) | <.0001* | 1 |
| During hospitalization 727 (5.9) | 14 (42.4) | 11.84 [547.25.01]* | |
it outpaced health systems everywhere. Competing with healthcare logistics and man power, SARS-CoV-2 challenged the cancer care continuum as we knew it. Our dataset adds to the real-life experience and demonstrates that continued care proved feasible and safe. In order to maintain active treatment, the hospital implemented structural changes to safeguard social distance and shorten the time spent at the oncology out-clinic. Telehealth was introduced with some mixed results: 1) A modified e-tool offering not only toxicity registration and management but also screened for SARS-CoV-2-related symptoms was well accepted. 2) However, we encountered reluctance to tele-consultations, which only 46.2% of patients regarded as a worthy surrogate to a face-to-face consultation. This probably resulted in the near similar number of specialist consultations, regardless of SARS-CoV-2 pandemic or not.

Telemedicine has been heralded as the silver lining in the cloud of the SARS-CoV-2 pandemic. Before it can be integrated into longitudinal cancer care, still some challenges remain. These concern technological issues to allow all patients (and care providers) to navigate telemedicine, but also operational issues such as the deployment of the support staff in the clinics, that will engage differently with their patients. And finally, policy makers will need to address payment parity in order to fulfill the full potential of telemedicine.

As in other cancer centers, we too saw a robust decline in diagnoses and appreciate the future excess in cancer morbidity (in case of stage shift and delayed treatment) and cost due to COVID-19-related disruption of care pathways.

Fear, uncertainty, and even mistrust toward health systems and hospitals may perhaps explain this backlog in cancer diagnoses. Adequate and timely information, an effective doctor/care team–patient relationship, and prompt psychological support are critical to overcome new physical or social barriers. This can be somewhat illustrated by the results of the patient questionnaire of patients’ reported perception of organizational measures. Even though 21.9% of patients claimed to be afraid of an interaction between cancer treatment and SARS-CoV-2 infection, over 90% felt safe (or quite safe) at the cancer care outpatient unit. We postulate that this may be explained by the support of the care team, the information provided about, and acceptance of hygienic measures (94.1% clear and reasonably clear).

In our final dataset, we demonstrated a low rate of detectable SARS-CoV-2 infections in cancer patients and compared their clinical characteristics to a national dataset by Sciensano, which included only hospitalized patients. Although this comparison is flawed, our analysis was retrospective and limited in sample size of both in- and outpatients, we believe that presenting these real-life data illustrate the fact that cancer patients received faster testing and screening in absence of or with mild symptoms, that they suffered the same symptoms, when infected with SARS-CoV-2, but may have demonstrated an overlap with chronic underlying afflictions. Finally, that they presented earlier, as assumed by the lack of symptoms at presentation.

This cohort analysis has notable limitations. We reported several datasets and retrospective cohort analyses retrieved from single University Hospital site (also SARS-CoV-2 reference center); therefore, results may not be generalizable to different settings. It is also important to note that the patient questionnaire was not randomized but on a voluntary basis; the patient population may therefore be sociodemographically homogeneous (additional data).

Table 3. (continued)

| Symptoms at presentation—n (%) | Patients without cancer (n = 12407) | Patients with solid cancer (n = 33) | P value | OR (95% CI) |
|-------------------------------|--------------------------------------|------------------------------------|---------|-------------|
| **Systemic symptoms**         |                                      |                                    |         |             |
| 9120 (73.5)                   | 22 (66.7)                            | .374†                              | 1.39 [67.2.86]† |
| **Respiratory symptoms**      |                                      |                                    |         |             |
| 9037 (72.8)                   | 26 (78.8)                            | .443†                              | .72 [31.1.66]† |
| **Gastrointestinal symptoms** |                                      |                                    |         |             |
| 2655 (21.4)                   | 10 (30.3)                            | .213†                              | .63 [30.1.32]† |
| **Neurological symptoms**     |                                      |                                    |         |             |
| 2146 (17.3)                   | 3 (9.1)                              | .213†                              | 2.09 [64.6.86]† |
| **Pain**                      |                                      |                                    |         |             |
| 2740 (22.1)                   | 7 (21.2)                             | .904†                              | 1.05 [46.2.43]† |
| **No symptoms**               | 683 (5.5)                            | 2 (6.1)                            | .703§    | .90 [23.7.80]§ |
| **Signs at presentation—n (%)** |                                      |                                    |         |             |
| **Respiratory signs**         | 10064 (81.1)                         | 25 (75.8)                          | .432†    | 1.37 [62.3.05]† |
| **Neurological signs**        | 104 (.8)                             | 0                                  | 1*       | Inf [0.07,Inf]* |
| **Temperature >38°C**         | 3717 (30.0)                          | 17 (51.5)                          | .007²    | .40 [20.0.80]² |
| **No signs**                  | 1534 (12.4)                          | 4 (12.1)                           | 1*       | 1.02 [36.4.01]* |

1Welch T-test.  
²Fisher’s exact test.  
§Chisquare test.

Rasschaert et al.
However, the experiences during this crisis will need to guide future cancer care provision. As the SARS-CoV-2 health crisis lingers on, we must address the possible ramifications of delaying or cancelling possible curative interventions and the societal costs that will ensue.\textsuperscript{30} Although we successfully introduced telemedicine in active cancer care and toxicity management, we need to learn from past experiences to prepare the opportunity to offer innovative state-of-the-art cancer care to patients and their caregivers from diagnosis onward. As the benefits of collecting and addressing patient-reported outcomes remotely in order to gain overall survival and reduce unplanned healthcare utilization are well known,\textsuperscript{33,34} offering a broader set of (web-based or electronic) features to a multitude of stakeholders can allow telemedicine to fulfill its role in a more longitudinal care path.

**Conclusion**

COVID-19 has impacted the clinical cancer management in many ways, and the full extent on care delivery remains for now largely unknown. This retrospective cohort analysis adds to the evidence that continuation of active cancer therapy and specialist visits is feasible and safe with the implementation of telemedicine.

**Acknowledgments**

We thank the study participants and the many physicians and nurses who reviewed, responded and interacted to symptom reports of our patients. We also thank all medical staff members involved in the patient centered care offered in the outpatient facilities during trying times.

**Author Contributions**

M.R. and P.V.D: Conceptualization. M.R. Data Curation, formal analysis, writing original draft, Writing review & editing. P.V. and L.D.P. Data Curation, Writing review & editing. T.M. and E.C. Resources, data curation. E.R. Validation, Methodology Formal analysis, Writing review & editing. S.A., A.J., P.V.D., M.P. Writing review & editing.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Ethical Approval**

All methods were carried out in accordance with relevant guidelines and regulations. Patient registries and epidemiological data were captured in accordance to the General Data Protection Regulation (GDPR) (EU) 22016/679 [21] on the protection of natural persons with regard to the processing of personal data and on the free movement of such data.

**Informed Consent**

Informed consent was waived and the study protocol was approved by the medical ethics committee of the Antwerp University Hospital. (EC UZA 20/39/506; EDGE:001380). Belgian Registration number: B.300202000180.

**Availability of Data and Materials**

The datasets generated and/or analyzed during the current study are not publicly available due to privacy issues but are available from the corresponding author on reasonable request.

**ORCID iD**

Marika Rasschaert  
https://orcid.org/0000-0003-3051-6481.

**Supplemental Material**

Supplemental material for this article is available online.

**References**

1. Petrosillo N, Viceconte G, Ergonoul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: Are they closely related?. *Clin Microbiol Infect*. 2020;26:729-734. DOI: 10.1016/j.cmi.2020.03.026.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020;579:265-269.
3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579:270-273.
4. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. *J Microbiol Immunol Infect*. 2020;54(2):159-163. DOI: 10.1016/j.jmii.2020.03.022.
5. https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/.
6. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. *Lancet Oncol*. 2020;21:335-337.
7. Albiges L, Foulon S, Bayle A, Gachot B, Pommert F, Willekens C, et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. *Nat Can (Que)*. 2020;1:965-975.
8. Van Dam PA, Huiizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, et al. SARS-CoV-2 and cancer: Are they really partners in crime? *Canc Treat Rev*. 2020;89:102068. DOI: 10.1016/j.ctrv.2020.102068.
9. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht Y, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient
demographics: A prospective cohort study. Lancet Oncol. 2020; 21:1309-1316.

10. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239-1242.

11. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:893-903.

12. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:904-913.

13. Williamson EL, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using open SAFELY. Nature. 2020;584:430-436. DOI: 10.1038/s41586-020-2521-4.

14. Tang LV, Hu Y. Poor clinical outcomes for patients with cancer during COVID-19 pandemic. Lancet Oncol. 2020;21:862-864.

15. De Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO open. 2020;5:e000947. doi:10.1136/esmoopen-2020-000947.

16. Waisberg F, Enrico D, Angel M, Chacón M. Cancer treatment adaptations in the COVID-19 era. JCO Oncology Practice. 2020;16:305-307.

17. Segelov E, Underhill C, Prenen H, Karapetis C, Jackson C, Nott L, et al. Practical considerations for treating patients with cancer in the COVID-19 pandemic. JCO Oncology Practice. 2020;16:467-482.

18. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic.

19. https://www.asco.org/asco-coronavirus-information.

20. Marron JM, Joffe S, Jagsi R, Spence RA, Hlubocky FJ. Ethics and resource scarcity: ASCO recommendations for the oncology community during the COVID-19 pandemic. J Clin Oncol. 2020;38:2201-2205.

21. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, et al. Managing cancer patients during the COVID-19 pandemic: An ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31:1320-1335.

22. Rasschaert M, Vaneloorster PJ, Mertens T, et al. The transition of toxicity management in routine oncology care during the SARS-CoV-2 pandemic. Br J Cancer. 2021;124(8):1366-1372. DOI: 10.1038/s41416-020-01235-3.

23. Patt D, Wilfong L, Toth S, et al. Telemedicine in community cancer care: How technology helps patients with cancer navigate a pandemic. JCP Oncology Practice. 2020;17:e11-e15.

24. Haase K, Avery J, Bryant-Lukosius D, et al. Patient and clinician perspectives of desired features for a web-based self-management program (icanmanage.ca): Exposing patients “hard work” of managing acute cancer. Support Care Canc. 2020;29(4):1989-1998. DOI: 10.1007/s00520-020-05683-8.

25. Henry BW, Block DE, Ciesla JR, McGowan BA, Vozenilek JA. Clinician behaviors in telehealth care delivery: a systematic review. Adv Health Sci Educ. 2017;22(4):869-888.

26. Shachar C, Engel J, Elwyn G, et al. Implications for telehealth in a postpandemic future. J Am Med Assoc. 2020;323:2275. doi:10.1001/jama.2020.7943.

27. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035-1044.

28. Wu J, Kwon D, Glover M et al. Changes in cancer management due to COVID-19 illness in patients with cancer in Northern Carolina. JCO Oncol practice. 2020;17(3):e377-e385. DOI: 10.1200/OCP.20.00790.

29. Clark JJ, Dwyer D, Pinwill N, Clark P, Johnson P, Hackshaw A. The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. Lancet Oncol. 2021;22:66-73.

30. COVIDsurg Collaborative. Elective surgery cancellations due to COVID-19 pandemic: Global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107:1440-1449.

31. Curtis JR, Kross EK, Stapleton RD. The importance of addressing advance care planning and decisions about do-not-resuscitate orders during novel coronavirus 2019 (COVID-19). J Am Med Assoc. 2020;323(8):1771-1772.

32. Holstead RG, Robinson AG. Discussing serious news remotely: Navigating difficult conversations during a pandemic. JCO Oncology Practice. 2020;16(7):363-368.

33. Denis F, Lethrosne C, Pannel N, Molinier O, Pointreau Y, Domont J, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst. 2017;109(9):dx029.

34. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016;34(6):557-565.